Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content +++ What are different measures of performance status? ++ Table Graphic Jump Location|Download (.pdf)|Print Key concept Performance status is a measure of functional capacity that is used as a clinical parameter to estimate survival in cancer patients.1 There are two metrics—Eastern Cooperative Oncology Group (ECOG) performance status and Karnofsky Performance Status (KPS)—used by oncologists and other medical professionals and for entry into clinical trials.1,2 Clinical scenario A 58-year-old woman with metastatic pancreatic cancer is unable to perform self-care and requires aid with daily activities of living, including bathing herself. She presents for follow-up with her oncologist. What is her performance status? Action items See Table below ++Table Graphic Jump LocationView Table||Download (.pdf) KARNOFSKY STATUS KARNOFSKY GRADE ECOG GRADE ECOG STATUS Normal, no complaints 100 0 Fully active, able to carry on all pre-disease performance without restriction Able to carry on normal activities; minor signs or symptoms of disease 90 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (eg, light house work or office work) Normal activity with effort, some signs or symptoms of disease 80 1 Able to care for self; unable to carry out normal activity or do active work 70 2 Ambulatory and capable of all self-care but unable to carry out any work activities; up and about >50% of waking hours Requires occasional assistance, but able to care for most needs 60 2 Requires considerable assistance and frequent medical care 50 3 Capable of only limited self-care, confined to bed or chair >50% of waking hours Disabled; requires special care and assistance 50 3 Severely disabled; hospitalization indicated, although death not imminent 30 4 Completely disabled; cannot carry out any self-care; totally confined to bed or chair Very sick; hospitalization necessary; active supportive treatment necessary 20 4 Moribund; fatal processes progressing rapidly 10 4 Dead 0 5 Dead ++ Table Graphic Jump Location|Download (.pdf)|Print References Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 1960;11(1):7-33. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. +++ How do I address fertility in young patients who plan to receive chemotherapy? ++ Table Graphic Jump Location|Download (.pdf)|Print Key concept The treatment of cancer in patients of reproductive age can be associated with the risk of infertility. Clinical scenario A 34-year-old woman was started on rituximab-DA EPOCH treatment for a primary B cell lymphoma of the mediastinum after diagnosis and completion of a staging work-up. She completed 6 courses of chemotherapy. Six months later, she became pregnant and delivered a healthy baby. Action item Men and women of ... Your Access profile is currently affiliated with '[InstitutionA]' and is in the process of switching affiliations to '[InstitutionB]'. Please click ‘Continue’ to continue the affiliation switch, otherwise click ‘Cancel’ to cancel signing in. Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Username Error: Please enter User Name Password Error: Please enter Password Forgot Password? Forgot Username? Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free a profile for additional features.